NEO · NeoGenomics, Inc.
$13.89
+1.98% last session
End-of-day data · updated 2026-07-28
Market cap
$2B
Enterprise value
$2B
Trailing P/E
—
Forward P/E
35.5
Dividend yield
—
Beta
1.74
Avg volume
3M
Employees
2K
2D change
-5.40%
5D change
-7.72%
10D change
-10.06%
30D change
-7.27%
60D change
24.90%
MTD change
-12.22%
YTD change
11.73%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — NEO
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-07-24
Latest call per bank · past 12 months
Morgan Stanley
Equal-Weight$8.00
-42.4% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-24 | Benchmark | Maintains | Buy | $11.00 → $16.00 |
| 2026-04-29 | Benchmark | Upgrade | Hold → Buy | $0.00 → $11.00 |
| 2026-04-29 | TD Cowen | Maintains | Buy | $13.00 → $14.00 |
| 2026-04-29 | Leerink Partners | Upgrade | Market Perform → Outperform | $12.00 → $25.00 |
| 2026-02-24 | Piper Sandler | Maintains | Overweight | $12.00 → $13.00 |
| 2026-02-17 | Needham | Maintains | Buy | $14.00 → $15.00 |
| 2026-01-12 | Needham | Reiterates | Buy | $14.00 |
| 2025-09-12 | TD Cowen | Maintains | Buy | $10.00 → $12.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-28
- RSI (14): RSI is 49 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 11.0% above the 50-day MA ($12.07).
- Price vs 200-day MA: Trading 25.0% above the 200-day MA ($10.72).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is negative (-0.29) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($4.84) and high ($15.16).
NEO Price Chart
Loading chart for NEO…
Fundamentals
About NeoGenomics, Inc.
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company offers molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. The company was founded in 2001 and is headquartered in Fort Myers, Florida.
More in Diagnostics & Research
TMO
Thermo Fisher Scientific Inc
$208B -3.3% YTD
DHR
Danaher Corporation
$138B -13.8% YTD
IDXX
IDEXX Laboratories, Inc.
$44B -17.8% YTD
A
Agilent Technologies, Inc.
$39B 1.9% YTD
NTRA
Natera, Inc.
$37B 12.6% YTD
IQV
IQVIA Holdings, Inc.
$36B -5.4% YTD
WAT
Waters Corporation
$36B -2.3% YTD
ILMN
Illumina, Inc.
$29B 44.5% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.